In vivo, preloading with unlabeled CD69 Ab administered 24 hours prior to tracer injection significantly reduced tracer uptake in the immune periphery (i.e., spleen) while enhanced tumor-specific 89Zr-DFO-CD69 Ab uptake, as indicated by the SUV values (Supplementary Fig. S6D) and BioD data (Supplementary Fig. S6E). The gene discussed is CD69; the disease is neoplasm.